Study Identifies Oxymetazoline as a Promising Candidate for Future Anti-Aging Research

Researchers searching for ways to slow biological aging are increasingly looking at medicines that are already available rather than developing entirely new drugs. Because approved medications have established safety profiles, repurposing them for new uses could dramatically shorten the time and cost required to bring potential anti-aging therapies into clinical practice.

A new study published in Nature Aging introduces a data-driven approach for identifying existing drugs that may target the biological processes underlying aging. Among the most promising candidates was an unexpected one: oxymetazoline, a medication commonly found in nasal sprays for congestion, eye drops for redness, and topical creams used to treat rosacea.

Mapping the biology of aging

Researchers from Northeastern University and Harvard Medical School based their work on the widely accepted hallmarks of aging, a collection of cellular and molecular changes that gradually accumulate throughout life. These include chronic inflammation, DNA damage, impaired communication between cells, declining cellular energy production, and other biological processes linked to age-related diseases.

The team identified 1,250 genes associated with one or more of these hallmarks and mapped them onto the human interactome—a large network that describes how proteins interact throughout the body. Their model included more than 500,000 known protein-protein interactions.

Rather than being randomly distributed, aging-related genes clustered together in distinct regions of the network. Each cluster represented different biological hallmarks of aging, revealing areas where multiple aging mechanisms overlap and potentially influence one another.

According to the researchers, this clustering is important because it suggests that targeting a single region of the network could affect several aging processes simultaneously, making drug interventions potentially more effective than previously thought.

Screening more than 6,000 drugs

Using this interactome map, the researchers evaluated 6,442 approved and experimental drugs listed in a major pharmaceutical database. They examined which medications target proteins located within or near aging-related clusters.

The analysis also considered whether each drug's known molecular and genetic effects were more likely to promote or counteract biological aging. This additional step allowed the researchers to prioritize compounds predicted to positively influence multiple longevity-related pathways.

One of the highest-ranking candidates was oxymetazoline. Although widely used to relieve nasal congestion and reduce eye redness, the drug has received little attention in aging research.

The computational analysis suggests oxymetazoline may improve communication between cells, a biological function that naturally deteriorates with age and contributes to declining function across multiple organs and tissues.

Why researchers are interested

Senior author Albert-László Barabási emphasized that the study does not identify a proven anti-aging treatment. Instead, it provides a systematic framework for identifying which existing drugs deserve further investigation.

The analysis also highlighted several other medications with possible anti-aging potential, including aspirin, which is already being studied for its effects on inflammation, cardiovascular health, and healthy aging. These findings reinforce the possibility that some familiar medicines may have broader biological effects than originally recognized.

Co-author Bnaya Gross explained that because aging-related genes cluster within the interactome, network-based drug discovery becomes much more practical. Rather than targeting a single biological pathway, future therapies may influence several hallmarks of aging simultaneously.

Researchers increasingly believe that slowing aging will likely require interventions affecting multiple biological systems rather than a single molecular target.

The findings remain preliminary

Although the computational framework identified several promising candidates, the researchers stress that none have yet been shown to slow aging in humans.

Oxymetazoline and the other highlighted drugs must first undergo laboratory testing in cells and animal models to determine whether they genuinely influence biological aging. Only if those studies produce encouraging results would carefully designed clinical trials in humans become appropriate.

The authors also caution that over-the-counter availability does not mean a medication is safe for long-term use outside its approved purpose. Dosage, treatment duration, and potential side effects could differ substantially when drugs are used for entirely new indications.

A roadmap rather than a treatment

Experts emphasize that people should not begin taking decongestants or other medications in hopes of extending their lifespan. The current findings are based entirely on computational network analysis and identify promising research targets rather than proven therapies.

Nevertheless, the study demonstrates how combining genetics, network science, and pharmacology can accelerate the search for treatments that promote healthy aging. Instead of testing thousands of drugs one by one, researchers can now use biological network maps to identify the most promising candidates for laboratory investigation.

As Barabási noted, many people hope that one day medicine will offer treatments capable of slowing aspects of aging itself. This new framework does not provide that therapy, but it may help scientists decide which existing drugs deserve the next stage of research on the path toward longer, healthier lives.